Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations

NCT02369484 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT02369484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02369484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Completed
Start date
September 16, 2015
Completion date
September 15, 2017
Enrollment
13 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc